- Institute of Metabolic Syndrome
- Heart and vessel Institute
- Institute of Endocrinology
- Institute of Experimental Medicine
- Institute of Molecular Biology and Genetics
- Polenov Neurosurgery Institute
- Institute of Oncology and Hematology
- Institute of Perinatology and Pediatrics
- Digital biobank
- Specimen storage
- Application development
- Digital transformation
- Intellectual property
- Business models
Obesity, fat tissue browning, heart failure with preserved EF, metabolically associated liver disease, chronic kidney disease, polygenic risk scales, CHIP, LOY, low grade inflammation, etc
Cardiomyopathies, congenital diseases, calcification, autoimmune and autoinflammatory diseases
DBS, VNS, spinal cord trauma, autonomic dysfunction
CAR-T, biclonal antibodies, cardiooncology, visualization, radiopharmacy and theranostics
World-class Research center 2020-2025
To create a biomedical R&D ecosystem that will develop and implement diagnostic and treatment technologies based on personalized medicine, including the assessment of genetic risks, methods of pharmacogenetics and pharmacogenomics, disease modelling, genome editing and drug development for gene therapy, biomedical cell products to improve the medical care quality and reduce mortality in cardiovascular diseases, metabolic comorbidities, cancer, selected infectious diseases, as well as in genetic diseases, including rare and undiagnosed diseases.
Scopus: 187
3 drugs + 3 new Radiopharmacy
2 vaccines
6 mobile applications and DSS
33 PhDs
44 Labs and Departments
% medical devices with AI registered and implemented in practice
12 items included in national clinical guidelines
14 PhDs
28 new scientists and 2 new labs with young leaders
The Boiling Point of Almazov Centre – a point of attraction for young entrepreneurs
About 10,000 scientific, educational, and university technology entrepreneurship events
Participation in RF Youth grant projects and all-Russian competitions of the Innovation Support Fund